Ayesha Sitlani
Overview
Explore the profile of Ayesha Sitlani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gieber L, Muturi-Kioi V, Malhotra S, Sitlani A
Pharmaceut Med
. 2023 Apr;
37(3):203-214.
PMID: 37115494
Monoclonal antibodies are an effective and growing class of pharmaceuticals for the treatment and prevention of a broad range of non-communicable and infectious diseases; however, most low- and middle-income countries...
2.
Strack A, Carballo-Jane E, Wang S, Xue J, Ping X, McNamara L, et al.
J Lipid Res
. 2012 Oct;
54(1):177-88.
PMID: 23103473
The use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D(2) (PGD(2)) with its G-protein coupled...
3.
Fattori E, Cappelletti M, Lo Surdo P, Calzetta A, Bendtsen C, Ni Y, et al.
J Lipid Res
. 2012 May;
53(8):1654-61.
PMID: 22611251
Successful development of drugs against novel targets crucially depends on reliable identification of the activity of the target gene product in vivo and a clear demonstration of its specific functional...
4.
Zhang L, McCabe T, Condra J, Ni Y, Peterson L, Wang W, et al.
Int J Biol Sci
. 2012 Feb;
8(3):310-27.
PMID: 22355267
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and...
5.
Lee A, Yates N, Ichetovkin M, Deyanova E, Southwick K, Fisher T, et al.
Clin Chem
. 2012 Jan;
58(3):619-27.
PMID: 22249652
Background: Current approaches to measure protein turnover that use stable isotope-labeled tracers via GC-MS are limited to a small number of relatively abundant proteins. We developed a multiplexed liquid chromatography-selected...
6.
Lo Surdo P, Bottomley M, Calzetta A, Settembre E, Cirillo A, Pandit S, et al.
EMBO Rep
. 2011 Nov;
12(12):1300-5.
PMID: 22081141
The protein PCSK9 (proprotein convertase subtilisin/kexin type 9) is a key regulator of low-density lipoprotein receptor (LDLR) levels and cardiovascular health. We have determined the crystal structure of LDLR bound...
7.
Ni Y, Di Marco S, Condra J, Peterson L, Wang W, Wang F, et al.
J Lipid Res
. 2010 Oct;
52(1):78-86.
PMID: 20959675
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) regulates LDL cholesterol levels by inhibiting LDL receptor (LDLr)-mediated cellular LDL uptake. We have identified a fragment antigen-binding (Fab) 1D05 which binds PCSK9 with...
8.
Ranalletta M, Bierilo K, Chen Y, Milot D, Chen Q, Tung E, et al.
J Lipid Res
. 2010 May;
51(9):2739-52.
PMID: 20458119
Cholesteryl ester transfer protein (CETP) has been identified as a novel target for increasing HDL cholesterol levels. In this report, we describe the biochemical characterization of anacetrapib, a potent inhibitor...
9.
Liu M, Wu G, Baysarowich J, Kavana M, Addona G, Bierilo K, et al.
J Lipid Res
. 2010 May;
51(9):2611-8.
PMID: 20453200
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that regulates hepatic low-density lipoprotein receptor (LDLR) levels in humans. PCSK9 has also been shown to regulate the levels of...
10.
Ni Y, Condra J, Orsatti L, Shen X, Di Marco S, Pandit S, et al.
J Biol Chem
. 2010 Feb;
285(17):12882-91.
PMID: 20172854
PCSK9 binds to the low density lipoprotein receptor (LDLR) and leads to LDLR degradation and inhibition of plasma LDL cholesterol clearance. Consequently, the role of PCSK9 in modulating circulating LDL...